Targeting a specific metabolic pathway in pancreatic cancer
Targeting pyrimidine biosynthesis in pancreatic ductal adenocarcinoma
This study is looking at a type of pancreatic cancer to find new ways to treat it by focusing on how the cancer cells grow and what they need to survive, which could lead to better treatment options for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-10886544 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a highly lethal cancer with limited treatment options. It aims to explore the unique metabolic needs of cancer cells, specifically targeting pyrimidine biosynthesis, which is crucial for their growth. By combining multiple approaches to inhibit this metabolic pathway, the research seeks to create a more effective treatment strategy that could overcome the limitations of current therapies. Patients may benefit from new treatment options that specifically target the metabolic vulnerabilities of their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma who have not responded well to conventional therapies.
Not a fit: Patients with early-stage pancreatic cancer or those whose cancer has not progressed may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: While targeting metabolic pathways in cancer is a growing area of interest, this specific approach to pyrimidine biosynthesis in PDAC is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Mullen, Nicholas James — University of Nebraska Medical Center
- Study coordinator: Mullen, Nicholas James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.